Loading...
Loading...
In the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher can last.
Ignyta currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked stocks in the med-drugs industry include Endo International plc ENDP, Hyperion Therapeutics, Inc. HPTX and Lannett Company, Inc. LCI. All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
ENDO INTL PLC ENDP: Free Stock Analysis Report
LANNETT INC LCI: Free Stock Analysis Report
HYPERION THERAP HPTX: Free Stock Analysis Report
IGNYTA INC RXDX: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Movers & ShakersGeneral
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in